Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2016

Open Access 01-12-2016 | Original investigation

Hepatic insulin resistance both in prediabetic and diabetic patients determines postprandial lipoprotein metabolism: from the CORDIOPREV study

Authors: A. Leon-Acuña, J. F. Alcala-Diaz, J. Delgado-Lista, J. D. Torres-Peña, J. Lopez-Moreno, A. Camargo, A. Garcia-Rios, C. Marin, F. Gomez-Delgado, J. Caballero, B. Van-Ommen, M. M. Malagon, P. Perez-Martinez, J. Lopez-Miranda

Published in: Cardiovascular Diabetology | Issue 1/2016

Login to get access

Abstract

Background/aims

Previous evidences have shown the presence of a prolonged and exaggerated postprandial response in type 2 diabetes mellitus (T2DM) and its relation with an increase of cardiovascular risk. However, the response in prediabetes population has not been established. The objective was to analyze the degree of postprandial lipemia response in the CORDIOPREV clinical trial (NCT00924937) according to the diabetic status.

Methods

1002 patients were submitted to an oral fat load test meal (OFTT) with 0.7 g fat/kg body weight [12 % saturated fatty acids (SFA), 10 % polyunsaturated fatty acids (PUFA), 43 % monounsaturated fatty acids (MUFA), 10 % protein and 25 % carbohydrates]. Serial blood test analyzing lipid fractions were drawn at 0, 1, 2, 3 and 4 h during postprandial state. Postprandial triglycerides (TG) concentration at any point >2.5 mmol/L (220 mg/dL) has been established as undesirable response. We explored the dynamic response in 57 non-diabetic, 364 prediabetic and 581 type 2 diabetic patients. Additionally, the postprandial response was evaluated according to basal insulin resistance subgroups in patients non-diabetic and diabetic without pharmacological treatment (N = 642).

Results

Prevalence of undesirable postprandial TG was 35 % in non-diabetic, 48 % in prediabetic and 59 % in diabetic subgroup, respectively (p < 0.001). Interestingly, prediabetic patients displayed higher plasma TG and large triacylglycerol-rich lipoproteins (TRLs-TG) postprandial response compared with those non-diabetic patients (p < 0.001 and p = 0.003 respectively). Moreover, the area under the curve (AUC) of TG and AUC of TRLs-TG was greater in the prediabetic group compared with non-diabetic patients (p < 0.001 and p < 0.005 respectively). Patients with liver insulin resistance (liver-IR) showed higher postprandial response of TG compared with those patients with muscle-IR or without any insulin-resistance respectively (p < 0.001).

Conclusions

Our findings demonstrate that prediabetic patients show a lower phenotypic flexibility after external aggression, such as OFTT compared with nondiabetic patients. The postprandial response increases progressively according to non-diabetic, prediabetic and type 2 diabetic state and it is higher in patients with liver insulin-resistance. To identify this subgroup of patients is important to treat more intensively in order to avoid future cardiometabolic complications.
Literature
1.
go back to reference Association AD. Standars of medical care in diabetes. Diabet Care. 2015;38(Suppl 1):S9–15. Association AD. Standars of medical care in diabetes. Diabet Care. 2015;38(Suppl 1):S9–15.
2.
go back to reference Paulweber B, Valensi P, Lindstrom J, Lalic NM, Greaves CJ, McKee M, et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab. 2010;42(Suppl 1):S3–36.CrossRef Paulweber B, Valensi P, Lindstrom J, Lalic NM, Greaves CJ, McKee M, et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab. 2010;42(Suppl 1):S3–36.CrossRef
3.
go back to reference Fujioka Y IY, Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb. 2009;16:145–54.CrossRefPubMed Fujioka Y IY, Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb. 2009;16:145–54.CrossRefPubMed
4.
go back to reference van Ommen BKJ, Heil SG, Kaput J. Challenging homeostasis to define biomarkers for nutrition related health. Mol Nutr Food Res. 2009;53:795–804.CrossRefPubMed van Ommen BKJ, Heil SG, Kaput J. Challenging homeostasis to define biomarkers for nutrition related health. Mol Nutr Food Res. 2009;53:795–804.CrossRefPubMed
5.
go back to reference Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol. 2011;9:258–70.CrossRefPubMed Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol. 2011;9:258–70.CrossRefPubMed
7.
go back to reference Nakamura A, Monma Y, Kajitani S, Kozu K, Ikeda S, Noda K, et al. Different postprandial lipid metabolism and insulin resistance between non-diabetic patients with and without coronary artery disease. J Cardiol. 2015;66:435–44.CrossRefPubMed Nakamura A, Monma Y, Kajitani S, Kozu K, Ikeda S, Noda K, et al. Different postprandial lipid metabolism and insulin resistance between non-diabetic patients with and without coronary artery disease. J Cardiol. 2015;66:435–44.CrossRefPubMed
8.
go back to reference Delgado-Lista J, Perez-Martinez P, Garcia-Rios A, Alcala-Diaz JF, Perez-Caballero AI, Gomez-Delgado F, Fuentes F, Quintana-Navarro G, Lopez-Segura F, Ortiz-Morales AM, Delgado-Casado N, Yubero-Serrano E, Camargo A, Marin C, Rodriguez-Cantalejo F, Gomez-Luna P, Ordovas J, Lopez-Miranda J, Perez-Jimenez F. Coronary diet intervention with olive oil and cardiovascular prevention study (CORDIOPREV study): rationale, methods and baseline characteristics. Am Heart J (in press). Delgado-Lista J, Perez-Martinez P, Garcia-Rios A, Alcala-Diaz JF, Perez-Caballero AI, Gomez-Delgado F, Fuentes F, Quintana-Navarro G, Lopez-Segura F, Ortiz-Morales AM, Delgado-Casado N, Yubero-Serrano E, Camargo A, Marin C, Rodriguez-Cantalejo F, Gomez-Luna P, Ordovas J, Lopez-Miranda J, Perez-Jimenez F. Coronary diet intervention with olive oil and cardiovascular prevention study (CORDIOPREV study): rationale, methods and baseline characteristics. Am Heart J (in press).
9.
go back to reference Garcia-Rios A, Gomez-Delgado FJ, Garaulet M, Alcala-Diaz JF, Delgado-Lista FJ, Marin C, et al. Beneficial effect of CLOCK gene polymorphism rs1801260 in combination with low-fat diet on insulin metabolism in the patients with metabolic syndrome. Chronobiol Int. 2014;31:401–8.CrossRefPubMed Garcia-Rios A, Gomez-Delgado FJ, Garaulet M, Alcala-Diaz JF, Delgado-Lista FJ, Marin C, et al. Beneficial effect of CLOCK gene polymorphism rs1801260 in combination with low-fat diet on insulin metabolism in the patients with metabolic syndrome. Chronobiol Int. 2014;31:401–8.CrossRefPubMed
10.
go back to reference Bastard JP, Faraj M, Karelis AD, Lavasseur J, Garrel D, Prud’homme D, et al. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test: response to Abdul-Ghani et al. Diabet Care. 2007;30:e83.CrossRef Bastard JP, Faraj M, Karelis AD, Lavasseur J, Garrel D, Prud’homme D, et al. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test: response to Abdul-Ghani et al. Diabet Care. 2007;30:e83.CrossRef
11.
go back to reference Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabet Care. 2007;30:89–94.CrossRef Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabet Care. 2007;30:89–94.CrossRef
12.
go back to reference Abdul-Ghani MA, Matsuda M, DeFronzo RA. Strong association between insulin resistance in liver and skeletal muscle in non-diabetic subjects. Diabet Med. 2008;25:1289–94.PubMed Abdul-Ghani MA, Matsuda M, DeFronzo RA. Strong association between insulin resistance in liver and skeletal muscle in non-diabetic subjects. Diabet Med. 2008;25:1289–94.PubMed
13.
go back to reference Mihas C, Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr Vasc Pharmacol. 2011;9:271–80.CrossRefPubMed Mihas C, Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr Vasc Pharmacol. 2011;9:271–80.CrossRefPubMed
14.
go back to reference Delgado-Lista J, Perez-Martinez P, Perez-Jimenez F, Garcia-Rios A, Fuentes F, Marin C, et al. ABCA1 gene variants regulate postprandial lipid metabolism in healthy men. Arterioscler Thromb Vasc Biol. 2010;30:1051–7.CrossRefPubMedPubMedCentral Delgado-Lista J, Perez-Martinez P, Perez-Jimenez F, Garcia-Rios A, Fuentes F, Marin C, et al. ABCA1 gene variants regulate postprandial lipid metabolism in healthy men. Arterioscler Thromb Vasc Biol. 2010;30:1051–7.CrossRefPubMedPubMedCentral
15.
go back to reference Tentolouris N, Stylianou A, Lourida E, Perrea D, Kyriaki D, Papavasiliou EC, et al. High postprandial triglyceridemia in patients with type 2 diabetes and microalbuminuria. J Lipid Res. 2007;48:218–25.CrossRefPubMed Tentolouris N, Stylianou A, Lourida E, Perrea D, Kyriaki D, Papavasiliou EC, et al. High postprandial triglyceridemia in patients with type 2 diabetes and microalbuminuria. J Lipid Res. 2007;48:218–25.CrossRefPubMed
16.
go back to reference Leonard A, Tun TK, Gaffney R, Sharma J, Gibney J, Boran G. Factors influencing elevated serum apolipoprotein B48 in diabetic and control participants. Br J Biomed Sci. 2014;71:145–50.PubMed Leonard A, Tun TK, Gaffney R, Sharma J, Gibney J, Boran G. Factors influencing elevated serum apolipoprotein B48 in diabetic and control participants. Br J Biomed Sci. 2014;71:145–50.PubMed
17.
go back to reference Lorenzo C, Wagenknecht LE, Rewers MJ, Karter AJ, Bergman RN, Hanley AJ, et al. Disposition index, glucose effectiveness, and conversion to type 2 diabetes: the insulin resistance atherosclerosis study (IRAS). Diabet Care. 2010;33:2098–103.CrossRef Lorenzo C, Wagenknecht LE, Rewers MJ, Karter AJ, Bergman RN, Hanley AJ, et al. Disposition index, glucose effectiveness, and conversion to type 2 diabetes: the insulin resistance atherosclerosis study (IRAS). Diabet Care. 2010;33:2098–103.CrossRef
18.
go back to reference Shojaee-Moradie F, Ma Y, Lou S, Hovorka R, Umpleby AM. Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol. Diabetes. 2013;62:4063–9.CrossRefPubMedPubMedCentral Shojaee-Moradie F, Ma Y, Lou S, Hovorka R, Umpleby AM. Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol. Diabetes. 2013;62:4063–9.CrossRefPubMedPubMedCentral
19.
go back to reference Zhu J, Lee B, Buhman KK, Cheng JX. A dynamic, cytoplasmic triacylglycerol pool in enterocytes revealed by ex vivo and in vivo coherent anti-Stokes Raman scattering imaging. J Lipid Res. 2009;50:1080–9.CrossRefPubMedPubMedCentral Zhu J, Lee B, Buhman KK, Cheng JX. A dynamic, cytoplasmic triacylglycerol pool in enterocytes revealed by ex vivo and in vivo coherent anti-Stokes Raman scattering imaging. J Lipid Res. 2009;50:1080–9.CrossRefPubMedPubMedCentral
20.
go back to reference Suryabhan LL, Chandrashekhar MI, Ratnendra RS, Prerna DN. A comparative study on the fasting and the postprandial dyslipidaemia in type 2 diabetes mellitus. JCDR. 2013;7:627–30. Suryabhan LL, Chandrashekhar MI, Ratnendra RS, Prerna DN. A comparative study on the fasting and the postprandial dyslipidaemia in type 2 diabetes mellitus. JCDR. 2013;7:627–30.
21.
go back to reference Pirillo A, Norata GD, Catapano AL. Postprandial lipemia as a cardiometabolic risk factor. Curr Med Res Opin. 2014;30:1489–503.CrossRefPubMed Pirillo A, Norata GD, Catapano AL. Postprandial lipemia as a cardiometabolic risk factor. Curr Med Res Opin. 2014;30:1489–503.CrossRefPubMed
22.
go back to reference Katsiki N, Kolovou G. Postprandial lipid profile in patients with type 2 diabetes. Curr Med Res Opin. 2014;30:121.CrossRefPubMed Katsiki N, Kolovou G. Postprandial lipid profile in patients with type 2 diabetes. Curr Med Res Opin. 2014;30:121.CrossRefPubMed
23.
go back to reference Boren J, Matikainen N, Adiels M, Taskinen MR. Postprandial hypertriglyceridemia as a coronary risk factor. Clin Chim Acta. 2014;431:131–42.CrossRefPubMed Boren J, Matikainen N, Adiels M, Taskinen MR. Postprandial hypertriglyceridemia as a coronary risk factor. Clin Chim Acta. 2014;431:131–42.CrossRefPubMed
24.
go back to reference Bansal N. Prediabetes diagnosis and treatment: a review. World J Diabet. 2015;6:296–303.CrossRef Bansal N. Prediabetes diagnosis and treatment: a review. World J Diabet. 2015;6:296–303.CrossRef
25.
go back to reference Senechal M, Slaght J, Bharti N, Bouchard DR. Independent and combined effect of diet and exercise in adults with prediabetes. Diabet, Metab Syndr Obes. 2014;7:521–9. Senechal M, Slaght J, Bharti N, Bouchard DR. Independent and combined effect of diet and exercise in adults with prediabetes. Diabet, Metab Syndr Obes. 2014;7:521–9.
26.
28.
go back to reference Taskinen MR, Boren J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239:483–95.CrossRefPubMed Taskinen MR, Boren J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239:483–95.CrossRefPubMed
29.
go back to reference Biswas SK, Mohtarin S, Mudi SR, Anwar T, Banu LA, Alam SM, et al. Relationship of Soluble RAGE with Insulin Resistance and Beta Cell Function during Development of Type 2 Diabetes Mellitus. J Diabet Res. 2015;2015:150325.CrossRef Biswas SK, Mohtarin S, Mudi SR, Anwar T, Banu LA, Alam SM, et al. Relationship of Soluble RAGE with Insulin Resistance and Beta Cell Function during Development of Type 2 Diabetes Mellitus. J Diabet Res. 2015;2015:150325.CrossRef
30.
go back to reference Pedrini MT, Kranebitter M, Niederwanger A, Kaser S, Engl J, Debbage P, et al. Human triglyceride-rich lipoproteins impair glucose metabolism and insulin signalling in L6 skeletal muscle cells independently of non-esterified fatty acid levels. Diabetologia. 2005;48:756–66.CrossRefPubMed Pedrini MT, Kranebitter M, Niederwanger A, Kaser S, Engl J, Debbage P, et al. Human triglyceride-rich lipoproteins impair glucose metabolism and insulin signalling in L6 skeletal muscle cells independently of non-esterified fatty acid levels. Diabetologia. 2005;48:756–66.CrossRefPubMed
31.
go back to reference Tatarczyk T, Ciardi C, Niederwanger A, Kranebitter M, Patsch JR, Pedrini MT. Postprandial triglyceride-rich lipoproteins induce hepatic insulin resistance in HepG2 cells independently of their receptor-mediated cellular uptake. Mol Cell Endocrinol. 2011;343:71–8.CrossRefPubMedPubMedCentral Tatarczyk T, Ciardi C, Niederwanger A, Kranebitter M, Patsch JR, Pedrini MT. Postprandial triglyceride-rich lipoproteins induce hepatic insulin resistance in HepG2 cells independently of their receptor-mediated cellular uptake. Mol Cell Endocrinol. 2011;343:71–8.CrossRefPubMedPubMedCentral
32.
go back to reference Du T, Yuan G, Zhang M, Zhou X, Sun X, Yu X. Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance. Cardiovasc Diabetol. 2014;13:146.CrossRefPubMedPubMedCentral Du T, Yuan G, Zhang M, Zhou X, Sun X, Yu X. Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance. Cardiovasc Diabetol. 2014;13:146.CrossRefPubMedPubMedCentral
33.
go back to reference Blanco-Rojo JF, Wopereis S, Perez-Martinez P, Quintana-Navarro GM. The insulin resistance phenotype (muscle or liver) interacts with the type of diet to determine changes in disposition Index after 2 years of intervention: the CORDIOPREV_DIAB randomised clinical trial. Diabetologia. 2016;59(1):67–76. doi:10.1007/s00125-015-3776-4.CrossRef Blanco-Rojo JF, Wopereis S, Perez-Martinez P, Quintana-Navarro GM. The insulin resistance phenotype (muscle or liver) interacts with the type of diet to determine changes in disposition Index after 2 years of intervention: the CORDIOPREV_DIAB randomised clinical trial. Diabetologia. 2016;59(1):67–76. doi:10.​1007/​s00125-015-3776-4.CrossRef
34.
go back to reference Purcell R, Latham SH, Botham KM, Hall WL, Wheeler-Jones CP. High-fat meals rich in EPA plus DHA compared with DHA only have differential effects on postprandial lipemia and plasma 8-isoprostane F2alpha concentrations relative to a control high-oleic acid meal: a randomized controlled trial. Am J Clin Nutr. 2014;100:1019–28.CrossRefPubMedPubMedCentral Purcell R, Latham SH, Botham KM, Hall WL, Wheeler-Jones CP. High-fat meals rich in EPA plus DHA compared with DHA only have differential effects on postprandial lipemia and plasma 8-isoprostane F2alpha concentrations relative to a control high-oleic acid meal: a randomized controlled trial. Am J Clin Nutr. 2014;100:1019–28.CrossRefPubMedPubMedCentral
35.
go back to reference Lopez S, Bermudez B, Pacheco YM, Villar J, Abia R, Muriana FJ. Distinctive postprandial modulation of beta cell function and insulin sensitivity by dietary fats: monounsaturated compared with saturated fatty acids. Am J Clin Nutr. 2008;88:638–44.PubMed Lopez S, Bermudez B, Pacheco YM, Villar J, Abia R, Muriana FJ. Distinctive postprandial modulation of beta cell function and insulin sensitivity by dietary fats: monounsaturated compared with saturated fatty acids. Am J Clin Nutr. 2008;88:638–44.PubMed
36.
go back to reference Farr S, Taher J, Adeli K. Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states. Cardiovasc Hematol Disord: Drug Targets. 2014;14:126–36.CrossRef Farr S, Taher J, Adeli K. Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states. Cardiovasc Hematol Disord: Drug Targets. 2014;14:126–36.CrossRef
37.
go back to reference Ohno Y, Miyoshi T, Noda Y, Oe H, Toh N, Nakamura K, et al. Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study. Cardiovasc Diabetol. 2014;13:71.CrossRefPubMedPubMedCentral Ohno Y, Miyoshi T, Noda Y, Oe H, Toh N, Nakamura K, et al. Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study. Cardiovasc Diabetol. 2014;13:71.CrossRefPubMedPubMedCentral
Metadata
Title
Hepatic insulin resistance both in prediabetic and diabetic patients determines postprandial lipoprotein metabolism: from the CORDIOPREV study
Authors
A. Leon-Acuña
J. F. Alcala-Diaz
J. Delgado-Lista
J. D. Torres-Peña
J. Lopez-Moreno
A. Camargo
A. Garcia-Rios
C. Marin
F. Gomez-Delgado
J. Caballero
B. Van-Ommen
M. M. Malagon
P. Perez-Martinez
J. Lopez-Miranda
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2016
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-016-0380-y

Other articles of this Issue 1/2016

Cardiovascular Diabetology 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.